KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2016 - 2022)

Emergent BioSolutions has reported Non-Current Deffered Revenue over the past 11 years, most recently at $5.9 million for Q1 2022.

  • For Q1 2022, Non-Current Deffered Revenue fell 88.76% year-over-year to $5.9 million; the TTM value through Mar 2022 reached $5.9 million, down 88.76%, while the annual FY2021 figure was $4.7 million, 91.53% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2022 was $5.9 million at Emergent BioSolutions, up from $4.7 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $85.6 million in Q4 2019 and troughed at $4.7 million in Q4 2021.
  • A 5-year average of $59.0 million and a median of $62.5 million in 2018 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: skyrocketed 327.49% in 2018 and later crashed 91.53% in 2021.
  • Year by year, Non-Current Deffered Revenue stood at $62.5 million in 2018, then soared by 36.96% to $85.6 million in 2019, then tumbled by 35.16% to $55.5 million in 2020, then crashed by 91.53% to $4.7 million in 2021, then rose by 25.53% to $5.9 million in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for EBS at $5.9 million in Q1 2022, $4.7 million in Q4 2021, and $45.3 million in Q3 2021.